Fatty liver disease: a new biobank aims to unlock the secrets of a silent epidemic
NCT ID NCT07051863
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study creates a large database and biobank of people with nonalcoholic fatty liver disease (NAFLD), a condition where fat builds up in the liver. Researchers will collect medical data and biological samples over time to study how the disease develops, progresses, and responds to treatments. The goal is to enable future studies that could lead to better diagnosis and care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this biobank could help researchers identify new risk factors, biomarkers, and potential treatments for fatty liver disease.
- What could go wrong
- This is an observational study, not a treatment trial. It collects data for future research, so it will not directly test any new therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2023
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patient wiht diagnosis of NAFLD/NASH/MAFLD
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Participant must be ≥ 18 years of age at the time of signing the informed consent 2. Participant willing to sign the informed consent form (ICF) and to complete all study-specific procedures and visits 3. To have a diagnosis of NAFLD/NASH/MAFLD followed at Epatocentro Ticino and collaborating/referring clinicians based on: 1. Liver biopsy with a histological evidence of NAFLD/NASH/MAFLD OR 2. Liver imaging (ultrasound, CT scan, MRI, CAP Controlled Attenuation Parameter) OR 3. Diagnosis of metabolic syndrome and liver fibrosis or cirrhosis without an alternative diagnosis; metabolic syndrome fulfilling one or more of the below mentioned conditions: * Abdominal obesity: a waist circumference of more than 35 inches (\>89cm) for women and more than 40 inches (\>102 cm) for men; * High blood pressure of 130/80 mm Hg or higher. Normal blood pressure is defined as less than 130 mm Hg for systolic pressure, and less than 80 mm Hg for diastolic pressure * Impaired fasting blood glucose. This means a level equal to or greater than 100 mg/dL (\>5.6 mmol/L) * High triglyceride levels of more than 150 mg/dL (\> 1.7mmol/L). * Low HDL (good) cholesterol: less than 40 mg/dL (\< 1.04 mmol/L) for men and less than 50 mg/dL (\< 1.29 mmol/L) for women 4. alcohol consumption less than 21 (males) or 14 (women) units per week in the 6 months before the enrolment and no history of excessive alcohol consumption in the 5 years before enrolment. One unit is 12g (grams) of pure alcohol; 10-12 grams of pure alcohol are contained in a 280-330 ml of beer, 150-180 ml of champagne, 30-40 ml of whisky or high-strength spirit, 60-80 ml of liqueur, and 100-120 ml of red wine Exclusion Criteria: 1. To have a diagnosis of type I diabetes mellitus 2. To have a concomitant liver disease 3. To take or have taken in the last 12 months before enrolment, on more than 50% of days, drugs that may cause liver steatosis (long-term high dose systemic corticosteroids (\> 20mg prednisone equivalent), amiodarone, methotrexate, tamoxifen, tetracycline, high dose estrogens and valproic acid) 4. Pregnancy and breast feeding.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fondazione Epatocentro Ticino
RECRUITINGLugano, Canton Ticino, 6900, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smartphone app may help curb the silent march of fatty liver disease toward cirrhosis
- AI and blood biomarkers could catch hidden liver damage
- A protein supplement may fight fatty liver in teens
- Can a single pill tackle both fatty liver and diabetes?
- Could a once-daily pill help children with fatty liver disease?
- A new MRI technique could see inside the Liver's metabolism without a biopsy